Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on August 31, 2023. The report discloses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new independent director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size to nine members.
- New Director Appointment: Zhen Su, M.D., M.B.A., was elected as an independent director to fill a newly created vacancy.
- Term and Committee: Dr. Su is designated as a Class III director serving until the 2025 annual meeting and was appointed to the Commercialization and Portfolio Committee.
Compensation and Governance Details
In connection with his election, Dr. Su received the following compensatory arrangements under the Company's Non-employee Director Compensation Policy:
- Cash Retainer: $50,000 annual cash retainer for Board service and $10,000 for committee service, prorated based on the effective date.
- Equity Grant: An option to purchase 68,000 shares of common stock under the 2022 Equity Incentive Plan.
- Option Terms: Exercise price of $1.28 per share (closing price on grant date). Vesting schedule includes one-third on the first anniversary, followed by monthly vesting of 1/36th of the total shares until the third anniversary.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Su.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the impact of the 68,000 new options on potential dilution.
- Confirm Dr. Su's specific qualifications and background relevant to the Commercialization and Portfolio Committee.
- Review the Company's 2022 Equity Incentive Plan to understand remaining share availability.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial health metrics.